Related Experiment Videos
Alpha fetoprotein inhibits aggregation of human platelets
1Department of General and Experimental Pathology, Medical Academy, Białystok, Poland.
Haematologia
|January 1, 1989
Summary
Human alpha-fetoprotein (AFP) significantly inhibits platelet aggregation at low concentrations. This effect is most pronounced with arachidonic acid, suggesting AFP plays a role in regulating blood clotting.
Area of Science:
- Biochemistry
- Hematology
- Immunology
Background:
- Human alpha-fetoprotein (AFP) is a major fetal serum protein with known immunomodulatory functions.
- Platelet aggregation is a critical process in hemostasis and thrombosis, influenced by various physiological and non-physiological activators.
Purpose of the Study:
- To investigate the inhibitory effect of human alpha-fetoprotein (AFP) on platelet aggregation.
- To determine the differential sensitivity of various platelet activators to AFP-induced inhibition.
Main Methods:
- Platelet-rich plasma was used to assess aggregation.
- Platelet aggregation was induced by physiological agonists (ADP, PAF, collagen, arachidonic acid) and a non-physiological activator (ionophore A 23,187).
- The effect of varying concentrations of human AFP (60-750 micrograms/ml) on platelet aggregation was measured.
Main Results:
- Human AFP inhibited platelet aggregation induced by physiological activators at concentrations below those found in human blood.
- Platelet aggregation stimulated by arachidonic acid showed 2-4 times greater sensitivity to AFP inhibition compared to other agonists.
- AFP did not affect platelet aggregation induced by ionophore A 23,187, even at high concentrations.
Conclusions:
- Human AFP possesses anti-platelet aggregation properties at physiologically relevant concentrations.
- AFP's inhibitory effect is more potent against arachidonic acid-induced aggregation, indicating a specific mechanism of action.
- AFP does not interfere with calcium-dependent platelet activation pathways.